Primary palliative care services must be better funded by both day and night
Editor-Guthrie's response to our editorial of 6 November on developing primary palliative care is helpful in pointing out that the new out of hours organisations are now responsible for three quarters of the week's on call hours, while primary care teams working during the day are responsible for only a quarter.
1 This of course means that general practitioners and district nurses working out of hours will often attend people dying at home.
Unfortunately such busy organisations are often extremely stretched to deal with the diverse out of hours workload, and hand over forms for identifying patients receiving palliative care who could deteriorate in the short term are in our experience rarely in place. Progress is being made by some practices which routinely notify NHS24 in Scotland or NHS Direct in England of such patients, as recommended, for instance, in the gold standards framework. 2 We do not yet know what effect the new call centre triaging and accompanying out of hours arrangements will have on helping patients to die at home if they so wish. Care by call centres can be problematic and perceived as impersonal. 3 This underscores the urgent need to develop plans for providing 24 hour care for dying people.
As out of hours services continue to evolve, the attempt to meet the last wishes of patients, many of whom would like to die at home if they could, must not be lost sight of. This means, as Guthrie highlights, that more community nurses and social support need to be available out of hours. Ways of targeting additional support at home for those with particularly complex needs should be explored, with community providers being encouraged to make greater use of the out of hours advice available from specialist palliative care services. Otherwise, as Levack et al suggest, 4 only those with the fewest symptoms and greatest personal resources will be able to die at home.
Specialist palliative care in dementia
Patients with dementia are unable to access appropriate palliative care
Editor-Hughes et al suggest that specialised units with outreach and liaison are needed for palliative care of patients with dementia.
1 The United States has taken a much more holistic approach than the United Kingdom in this area. Although several papers have been published over the past few years that highlight the need for palliative care for such patients, 2 3 little more than lip service is paid to this group of patients. In our experience, even if patients with dementia develop advanced cancer they are seldom admitted to specialist palliative care units, and palliative care teams are only too ready to declare such patients as having no specialist needs or not being appropriate for their service.
Evidence shows that where psychiatry and palliative care teams collaborate well, appropriate palliative care can be delivered to patients with advanced dementia wherever they may be located. 4 The need for bereavement care for relatives where social death occurs many months or years before the physical death must also be included.
We advocate Hughes et al's suggestion that through outreach and liaison, palliative care for people with dementia can be delivered in the community, including in nursing and residential homes. Palliative care services need to look beyond cancer. Patients with dementia and their families have a high symptom burden and all too often are not offered or provided with the care they require. 2 Incontinence of bowel and bladder and impairment in other activities of daily living also need special attention.
Broadening the scope of palliative care services to meet the needs of people with dementia would be a welcome step, particularly in developing regions of the world. India's 10/66 dementia research group has developed a community based intervention programme that uses trained community health workers to identify people with dementia and deliver simple community based interventions in the community. 3 This training programme takes into consideration the specific needs of dementia care while adhering to the general principles of palliative care. 
. . . and hope for terminal care at home is needed in developed countries
Editor-Good quality care for advanced dementia is right and laudable and should be supported. However, we echo the view of Sivaraman (above) that home based palliative care of dementia is important and badly needed in the developed world as well as the developing world. We think that the methods required will also be quite different for cancer care. We have been developing and pioneering skills around managing people with advanced dementia at home for several years. This is a welcome initiative for carers and has produced some excellent feedback from carers and also good observational data for patients. The skills required are diverse and certainly bear little resemblance to any one discipline. Antipsychotic and antidepressant drugs remain important, but physical care, aids, mobility, bowel care, pressure care, and other symptom control are essential components.
The assumption in the editorial by Hughes et al that pain relief is central is worrying.
1 This seems to be simple transference of the issue of pain in cancer care. We have seen severely ill and behaviourally disturbed patients with dementia nearly die from low doses of opiates, and pain relief may not necessarily be required in such cases very often. Palliative care teams have helped in the work we have been doing, but not often in a central way.
We would therefore caution against translating too many of the lessons of cancer care into dementia care. A strong similarity with cancer care should be the opportunity to think about terminal care occurring at home when possible. However, the situations are not the same, and the expertise required for the care of advanced dementia has several aspects making it substantially different from cancer care.
Managing osteoarthritis of the knee

Conclusions about use of NSAIDs are misleading
Editor-The meta-analysis by Bjordal et al of randomised controlled trials assessing the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) in osteoarthritic knee pain is technically well done, but the authors' conclusions are misleading.
1 They assert that the mean change in pain, as measured on a visual analogue scale, over placebo was 10.1 mm (95% confidence interval 7.4 to 12.8) and claim a non-relevant difference, since the minimal clinically perceptible difference was 9.7 mm. 2 They mixed up the interpretations at group and individual levels. Indeed, 9.7 is the perceptible difference at the individual level (a change lower than 9.7 mm would not be perceived by the patient). However, the 10.1 mm estimate assessed by Bjordal et al makes sense only at the group level.
To understand this multilevel interpretation better, we performed some calculations, classifying patients as improved or not if they achieved a change greater than 10.1 mm. Thus, hypothesising that in the placebo group, the change equals 5+20 mm, 40.1% of the placebo group patients would show improvement (under the reasonable assumption of a normal distribution of change in pain on a visual analogue scale). A treatment effect of 10.1 mm leads to a mean change of 15.1 mm in the experimental group, and 60.1% of patients would therefore show improvement. The number of patients needed to treat is then estimated at 5.0. In the same way, if the difference in the placebo group was 20±20 mm, 69.2% of patients would show improvement in this group and 84.3% in the experimental group, and the number needed to treat would then be 6.6. These examples show that using the minimal clinically perceptible difference to interpret changes at the group level is inadequate: a small variation at the group level does not mean no clinically relevant change in the individuals of the group. 
Authors' reply
Editor-Tubach et al say that we misinterpret data by confusing group responses and individual responses. They present hypothetical calculations that supposedly show a number needed to treat of 5-6.6 for non-steroidal anti-inflammatory drugs (NSAIDs) in osteoarthritis of the knee. Their calculations are based on a weighted mean difference of 10.1 mm on a visual analogue scale from our analysis. However, we showed that this group response value was inflated by patient selection bias in a subgroup of trials. When this subgroup of biased trials was removed from analysis in our paper, the unbiased weighted mean difference fell to 5.9 mm (3.8 to 7.9).
As a benchmark for response, Tubach et al have selected what the inventors termed the "minimally perceptible difference" at 9.7 mm on the visual analogue scale.
1 A more clinically relevant benchmark in knee osteoarthritis would be the "minimal clinically important difference," which corresponds to 19.9 mm on the scale. 2 Using the unbiased weighted mean difference and the latter benchmark for treatment success, the resulting number needed to treat is in the 9-20 range.
Tubach et al make a point of the fact that the occasional patient may experience benefit from NSAID treatment. In our view, it seems more relevant to question if patients should be put at jeopardy for adverse effects from oral NSAIDs when only a few of them are likely to notice if their NSAID is replaced by a placebo.
We stand by our conclusion that there is a lack of evidence for clinically relevant effects from oral NSAIDs in knee osteoarthritis pain. 
Holistic approach is important
Editor-The editorial by MacAuley on managing osteoarthritis of the knee provides a welcome emphasis on the EULAR recommended, holistic, multidisciplinary approach to the condition.
1
Excessive prescribing of non-steroidal anti-inflammatory drugs in primary care reflects the dependence of health professionals on "medicines based evidence" rather than evidence based medicine and the chronic underinvestment in other approaches to osteoarthritis of the knee. 2 No reference was made to evidence of benefit of weight loss programmes linked to exercise; this is important, since increasing levels of obesity and incident knee osteoarthritis are strongly associated. 3 Even relatively small amounts of weight loss can reduce pain and improve activity levels. At the point at which knee replacement is appropriate, severely disabled patients with a high body mass index may be denied surgery.
MacAuley comments that physiotherapy may delay decline. Community physiotherapists could have a central role in the treatment of knee osteoarthritis, using motivating clinical skills for individual or group exercise programmes, gait retraining, taping, falls prevention, walking aids, footwear advice, and pain relief techniques including acupuncture and steroid injections. 4 The new cohort of NHS physiotherapy practitioners with extended scope can independently assess, treat, and improve appropriateness of referral to orthopaedic consultants.
5
A physiotherapist may be a highly appropriate lead musculoskeletal specialist in primary care, providing a functional approach to treatment to minimise disability for people with osteoarthritis of the knee and overall offering far more in a consultation than the average general practitioner.
The large community disability burden and high knee pain referral rates to orthopaedic specialists, warrant intervention at a population level and an integrated care pathway for osteoarthritis of the knee. 
Opioids help manage pain in osteoarthritis
Editor-MacAuley raises an important point about the poor long term management of pain in osteoarthritis of the knee.
1
A recent survey carried out by Arthritis Care to assess the impact of osteoarthritis on patients showed that 81% of the sample said they experience constant pain and that when their osteoarthritis is bad, 69% have difficulty carrying out even the simplest of daily household tasks. 2 Exercise is undoubtedly of benefit to patients with mild to moderate osteoarthritis, so the priority of healthcare professionals should be the symptomatic relief of chronic pain. Along with paracetamol and non-steroidal anti-inflammatory drugs there is further ammunition for pain relief. Opioids can and should be considered in these patients. As stated by the Pain Society, 3 the primary effect of the appropriate use of opioids in chronic pain is analgesia that leads to improved function, sleep, and reduced distress. Their use may also result in reduced use of other analgesics.
With improved education of healthcare professionals and the patient, opioid treatment can be initiated and managed in primary care through developing an individualised treatment plan in discussion with the patient. Doctors in general practice should therefore recognise that appropriate prescribing of opioids can offer a substantial improvement in a patient's quality of life. Firstly, the data are compatible with a non-specific effect caused by touch: exercise has a significantly positive effect on back pain which can be enhanced by touch. If this "devil's advocate" view is correct, the effects have little to do with spinal manipulation itself.
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Secondly, which of the three professional groups (chiropractors, osteopaths, physiotherapists) generated the largest effect size is relevant. This might significantly influence the referral pattern. A post-hoc analysis might answer this question.
Lastly, the study monitored only serious adverse effects. Data show that minor adverse effects occur in about 50% of patients after spinal manipulation. 2 Such adverse events might then also influence general practitioners' referrals.
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